Takeda Pharmaceutical Company Limited
TKPHF
$34.39
-$1.61-4.47%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.07% | -4.63% | -1.13% | -2.36% | -0.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.07% | -4.63% | -1.13% | -2.36% | -0.34% |
| Cost of Revenue | -4.78% | -2.85% | 7.28% | -6.13% | 6.32% |
| Gross Profit | 7.57% | -5.53% | -5.10% | -0.16% | -3.80% |
| SG&A Expenses | 3.42% | -4.75% | 2.27% | 1.02% | -2.10% |
| Depreciation & Amortization | 0.42% | -4.61% | 0.68% | -0.63% | 219.51% |
| Other Operating Expenses | -52.60% | 136.67% | -87.81% | 16.21% | 85.68% |
| Total Operating Expenses | -7.12% | 1.86% | -2.44% | 1.27% | 37.16% |
| Operating Income | 952.52% | -29.52% | 5.84% | -23.20% | -96.24% |
| Income Before Tax | 401.64% | -76.21% | 19.00% | -119.93% | -58.28% |
| Income Tax Expenses | 1,059.27% | 47.50% | -31.15% | 90.81% | 105.59% |
| Earnings from Continuing Operations | 330.67% | -112.84% | 40.74% | -3,254.14% | -78.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -102.22% | -18.96% | 23.81% | -131.29% | -27.20% |
| Net Income | 331.11% | -112.92% | 40.77% | -3,229.30% | -78.22% |
| EBIT | 952.52% | -29.52% | 5.84% | -23.20% | -96.24% |
| EBITDA | 58.99% | -17.86% | 3.90% | -16.69% | -61.42% |
| EPS Basic | 332.93% | -112.96% | 41.16% | -3,192.31% | -78.45% |
| Normalized Basic EPS | 342.27% | -33.80% | 2.92% | -29.64% | -116.67% |
| EPS Diluted | 325.71% | -113.18% | 40.82% | -3,192.31% | -78.45% |
| Normalized Diluted EPS | 338.30% | -32.68% | 2.69% | -29.64% | -116.67% |
| Average Basic Shares Outstanding | -0.39% | -0.34% | -0.27% | 0.84% | 1.04% |
| Average Diluted Shares Outstanding | 1.28% | -1.99% | -0.06% | 0.84% | 1.04% |
| Dividend Per Share | -- | 2.85% | -- | 1.56% | -- |
| Payout Ratio | -0.76% | -8.45% | -0.19% | 0.97% | 3.68% |